Novel agents in ovarian cancer

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S et al.: Cancer statistics, 2000 CA. Cancer J. Clin. (2000) 50:7-33.
   Google Scholar
• MCGUIRE WP, HOSKINS WJ, BRADY MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. (1996) 334:1-6.
   PubMed Web of Science ®Google Scholar
• BEREK JS, BERTELSEN K, DU BOIS A et al.: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. (1999) 10(Suppl. 1):87-92.
   Google Scholar
• OZOLS RF, BUNDY BN, GREER BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. (2003) 21:3194-3200.
   PubMed Web of Science ®Google Scholar
• BOOKMAN MA: GOG0182-ICON5: 5-arm Phase III randomized trial of paclitaxel (P) and carboplatin (C) vs. combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J. Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5002.
   PubMedGoogle Scholar
• BALKWILL F, BAST RC, BEREK J et al.: Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris memorial trust. Eur. J. Cancer (2003) 39:1818-1827.
   PubMed Web of Science ®Google Scholar
• NIELSEN JS, JAKOBSEN E, HOLUND B et al.: Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int. J. Gynecol. Cancer (2004) 14:1086-1096.
   PubMed Web of Science ®Google Scholar
• OWENS OJ, STEWART C, BROWN I et al.: Epidermal growth factor receptors (EGFR) in human ovarian cancer. Br. J. Cancer (1991) 64:907-910.
   PubMed Web of Science ®Google Scholar
• BERCHUCK A, KAMEL A, WHITAKER R et al.: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. (1990) 50:4087-4091.
   PubMed Web of Science ®Google Scholar
• LEARY JA, EDWARDS BG, HOUGHTON CR et al.: Amplification of HER-2/neu oncogene in human ovarian cancer. Int. J. Gynecol. Cancer (1992) 2:291-294.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
   PubMed Web of Science ®Google Scholar
• RUBIN SC, FINSTAD CL, FEDERICI MG et al.: Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer (1994) 73:1456-1459.
   PubMed Web of Science ®Google Scholar
• GORDON MS, MATEI D, AGHAJANIAN C et al.: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. (2006) 24:4324-4332.
   PubMed Web of Science ®Google Scholar
• CAMPIGLIO M, ALI S, KNYAZEV PG et al.: Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J. Cell Biochem. (1999) 73:522-532.
   PubMed Web of Science ®Google Scholar
• DEL CARMEN MG, RIZVI I, CHANG Y et al.: Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J. Natl.Cancer Inst. (2005) 97:1516-1524.
   PubMed Web of Science ®Google Scholar
• SEWELL JM, MACLEOD KG, RITCHIE A et al.: Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (“Iressa”). Br. J. Cancer (2002) 86:456-462.
   PubMed Web of Science ®Google Scholar
• AGUS DB, GORDON MS, TAYLOR C et al.: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. (2005) 23:2534-2543.
   PubMed Web of Science ®Google Scholar
• PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353:1659-1672.
   PubMed Web of Science ®Google Scholar
• ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353:1673-1684.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
   Google Scholar
• GORDON AN, FINKLER N, EDWARDS RP et al.: Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer (2005) 15:785-792.
   PubMed Web of Science ®Google Scholar
• SCHILDER RJ, SILL MW, CHEN X et al.: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. (2005) 11:5539-5548.
   PubMed Web of Science ®Google Scholar
• BOOKMAN MA, DARCY KM, CLARKE-PEARSON D et al.: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. (2003) 21:283-290.
   PubMed Web of Science ®Google Scholar
• AGHAJANIAN PS, DEROSA F, GERST S et al.: A Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings. Vol. 23, No. 16S, Part I of II (June 1 Supplement), (2005):5047.
   Web of Science ®Google Scholar
• BLANK SV, CURTIN JP, GOLDMAN NA, RUNOWICZ CD et al.: Report of first-stage accrual for NCI 5886, a Phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5076.
   Google Scholar
• CHIEN KR: Herceptin and the heart – a molecular modifier of cardiac failure. N. Engl. J. Med. (2006) 354:789-790.
   PubMed Web of Science ®Google Scholar
• AUERSPERG N, MAINES-BANDIERA SL, DYCK HG et al.: Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab. Invest. (1994) 71:510-518.
   PubMed Web of Science ®Google Scholar
• MATEI D, EMERSON RE, LAI YC et al.: Autocrine activation of PDGFRα promotes the progression of ovarian cancer. Oncogene (2006) 25:2060-2069.
   PubMed Web of Science ®Google Scholar
• HENRIKSEN R, FUNA K, WILANDER E et al.: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. (1993) 53:4550-4554.
   PubMed Web of Science ®Google Scholar
• APTE SM, BUCANA CD, KILLION JJ et al.: Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol. Oncol. (2004) 93:78-86.
   PubMed Web of Science ®Google Scholar
• LASSUS H, SIHTO H, LEMINEN A et al.: Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br. J. Cancer (2004) 91:2048-2055.
   PubMed Web of Science ®Google Scholar
• CRICKARD K, GROSS JL, CRICKARD U et al.: Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol. Oncol. (1994) 55:277-284.
   PubMed Web of Science ®Google Scholar
• VALVE E, MARTIKAINEN P, SEPPANEN J et al.: Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. Int. J. Cancer (2000) 88:718-725.
   PubMed Web of Science ®Google Scholar
• MATSUI T, HEIDARAN M, MIKI T et al.: Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science (1989) 243:800-804.
   PubMed Web of Science ®Google Scholar
• HART CE, FORSTROM JW, KELLY JD et al.: Two classes of PDGF receptor recognize different isoforms of PDGF. Science (1988) 240:1529-1531.
   PubMed Web of Science ®Google Scholar
• ERIKSSON A, SIEGBAHN A, WESTERMARK B et al.: PDGF α- and β-receptors activate unique and common signal transduction pathways. EMBO J. (1992) 11:543-550.
   PubMed Web of Science ®Google Scholar
• LI L, WANG L, ZHANG W et al.: Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. (2004) 24:1973-1979.
   PubMed Web of Science ®Google Scholar
• HUANG JS, HUANG SS, DEUEL TF: Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors. Cell (1984) 39:79-87.
   PubMed Web of Science ®Google Scholar
• YU J, MOON A, KIM HR: Both platelet-derived growth factor receptor (PDGFR)-α and PDGFR-β promote murine fibroblast cell migration. Biochem. Biophys. Res. Commun. (2001) 282:697-700.
   PubMed Web of Science ®Google Scholar
• UREN A, YU JC, GHOLAMI NS et al.: The α PDGFR tyrosine kinase mediates locomotion of two different cell types through chemotaxis and chemokinesis. Biochem. Biophys. Res. Commun. (1994) 204:628-634.
   PubMed Web of Science ®Google Scholar
• GREENHALGH DG, SPRUGEL KH, MURRAY MJ et al.: PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am. J. Pathol. (1990) 136:1235-1246.
   PubMed Web of Science ®Google Scholar
• FRANKLIN WA, CHRISTISON WH, COLLEY M et al.: In situ distribution of the β-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res. (1990) 50:6344-6348.
   PubMed Web of Science ®Google Scholar
• MATEI D, CHANG DD, JENG MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin. Cancer Res. (2004) 10:681-690.
   PubMed Web of Science ®Google Scholar
• PIETRAS K, RUBIN K, SJOBLOM T et al.: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. (2002) 62:5476-5484.
   PubMed Web of Science ®Google Scholar
• BERGERS G, SONG S, MEYER-MORSE N et al.: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. (2003) 111:1287-1295.
   PubMed Web of Science ®Google Scholar
• MATEI REE D, MENNING N, SCHILDER J et al.: Clinical activity of imatinib mesylate in combination with docetaxel in patients with advanced, platinum-resistant ovarian cancer – Hoosier Oncology Group GYN03-62. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5091.
   Google Scholar
• KANTARJIAN H, JABBOUR E, GRIMLEY J et al.: Dasatinib. Nat. Rev. Drug Discov. (2006) 5:717-718.
   PubMed Web of Science ®Google Scholar
• SCHITTENHELM MM, SHIRAGA S, SCHROEDER A et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. (2006) 66:473-481.
   PubMed Web of Science ®Google Scholar
• CORTES J, ROUSSELOT P, KIM DW et al.: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood (2007) 109:3207-3213.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, KANTARJIAN HM, BACCARANI M et al.: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2007) 109:2303-2309.
   PubMed Web of Science ®Google Scholar
• LOIZOS N, XU Y, HUBER J et al.: Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol. Cancer Ther. (2005) 4:369-379.
   PubMed Web of Science ®Google Scholar
• JAYSON GC, PARKER GJ, MULLAMITHA S et al.: Blockade of platelet-derived growth factor receptor-β by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin.Oncol. (2005) 23:973-981.
   PubMed Web of Science ®Google Scholar
• FERRARA N, CARVER-MOORE K, CHEN H et al.: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 380:439-442.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, JAIN RK: Angiogenesis in cancer and other diseases. Nature (2000) 407:249-257.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. (2002) 29:15-18.
   PubMed Web of Science ®Google Scholar
• LIOTTA LA, STEEG PS, STETLER-STEVENSON WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 64:327-336.
   PubMed Web of Science ®Google Scholar
• GADDUCCI A, VIACAVA P, COSIO S et al.: Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res. (2003) 23:549-556.
   PubMed Web of Science ®Google Scholar
• STONE PJ, GOODHEART MJ, ROSE SL et al.: The influence of microvessel density on ovarian carcinogenesis. Gynecol. Oncol. (2003) 90:566-571.
   PubMed Web of Science ®Google Scholar
• GADDUCCI A, FERDEGHINI M, FANUCCHI A et al.: Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. (1999) 19:1401-1405.
   PubMed Web of Science ®Google Scholar
• GHOSH S, MAITY P: Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients. Pathol. Oncol. Res. (2004) 10:104-108.
   PubMed Web of Science ®Google Scholar
• OBERMAIR A, TEMPFER C, HEFLER L et al.: Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br. J. Cancer (1998) 77:1870-1874.
   PubMed Web of Science ®Google Scholar
• Wong C, Wellman TL, Lounsbury KM: VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer. Gynecol. Oncol. (2003) 91:513-517.
   PubMed Web of Science ®Google Scholar
• HATA K, UDAGAWA J, FUJIWAKI R et al.: Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology (2002) 62:340-348.
   PubMed Web of Science ®Google Scholar
• ZHANG L, YANG N, PARK JW et al.: Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. (2003) 63:3403-3412.
   PubMed Web of Science ®Google Scholar
• BOOCOCK CA, CHARNOCK-JONES DS, SHARKEY AM et al.: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. (1995) 87:506-516.
   PubMed Web of Science ®Google Scholar
• KE L, QU H, NAGY JA et al.: Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur. J. Cancer (1996) 32A:2467-2473.
   PubMed Web of Science ®Google Scholar
• NAGY JA, MASSE EM, HERZBERG KT et al.: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. (1995) 55:360-368.
   PubMed Web of Science ®Google Scholar
• OLSON TA, MOHANRAJ D, CARSON LF et al.: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. (1994) 54:276-280.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, KONISHI I, MANDAI M et al.: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer (1997) 76:1221-1227.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MATLI MR et al.: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95:1789-1797.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-844.
   PubMed Web of Science ®Google Scholar
• FERRARA N: VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer (2002) 2:795-803.
   PubMed Web of Science ®Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:2184-2191.
   PubMed Web of Science ®Google Scholar
• SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non small cell lung cancer, an ECOG trial. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):S2.
   Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• COBLEIGH MA, MILLER KD, RUGO HS> et al.: Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res. Treat. (2002) 76:S37.
   Google Scholar
• BURGER RA, SILL M, MONK BJ, GREER B, SOROSKY J: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. Proc. Am. Soc. Clin. Oncol. (2005) 23:4575. Abstract 5009.
   Google Scholar
• GARCIA AA, OZA AM, HIRTE H et al.: Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. Proc. Am. Soc. Clin. Oncol. (2005) 23:4555. Abstract 5000.
   Google Scholar
• CANNISTRA SA, MATULONIS U, PENSON R et al.: Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5006.
   Google Scholar
• CANNISTRA SA, OTTENSMEIER C, NILOFF J et al.: Expression and function of β 1 and α v β 3 integrins in ovarian cancer. Gynecol. Oncol. (1995) 58:216-225.
   PubMed Web of Science ®Google Scholar
• WELCH HH S, SCHILDER RJ, ELIT L et al.: Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH Phase II consortium trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5084.
   Google Scholar
• PARKER N, TURK MJ, WESTRICK E et al.: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Ann. Biochem. (2005) 338:284-293.
   Google Scholar
• KNUTSON KL, KRCO CJ, ERSKINE CL et al.: T-cell immunity to the folate receptor α is prevalent in women with breast or ovarian cancer. J. Clin. Oncol. (2006) 24:4254-4261.
   PubMed Web of Science ®Google Scholar
• LEAMON CP, LOW PS: Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA (1991) 88:5572-5576.
   PubMed Web of Science ®Google Scholar
• WANG S, LEE RJ, CAUCHON G et al.: Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA (1995) 92:3318-3322.
   PubMed Web of Science ®Google Scholar
• TURK MJ, WATERS DJ, LOW PS: Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. (2004) 213:165-172.
   PubMed Web of Science ®Google Scholar
• ZHAO XB, LEE RJ: Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug Deliv. Rev. (2004) 56:1193-1204.
   PubMed Web of Science ®Google Scholar
• MELANI C, FIGINI M, NICOSIA D et al.: Targeting of IL-2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. (1998) 58:4146-4154.
   PubMed Web of Science ®Google Scholar
• KONNER JA, AHMED S, GERST S et al.: Phase I study of MORAb-003, a humanized anti-folate receptor-α monoclonal antibody, in platinum resistant ovarian cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5027.
   Google Scholar
• CHAN BM, MATSUURA N, TAKADA Y et al.: In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science (1991) 251:1600-1602.
   PubMed Web of Science ®Google Scholar
• FELDING-HABERMANN B, O'TOOLE TE, SMITH JW et al.: Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA (2001) 98:1853-1858.
   PubMed Web of Science ®Google Scholar
• REINMUTH N, LIU W, AHMAD SA et al.: α v β3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. (2003) 63:2079-2087.
   Google Scholar
• KHALILI P, ARAKELIAN A, CHEN G et al.: A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. (2006) 5:2271-2280.
   PubMed Web of Science ®Google Scholar
• EBLE JA, HAIER J: Integrins in cancer treatment. Curr. Cancer Drug Targets (2006) 6:89-105.
   PubMed Web of Science ®Google Scholar
• CRUET-HENNEQUART S, MAUBANT S, LUIS J et al.: α(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene (2003) 22:1688-1702.
   PubMed Web of Science ®Google Scholar
• STROBEL T, CANNISTRA SA: β1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol. Oncol. (1999) 73:362-367.
   PubMed Web of Science ®Google Scholar
• STUPACK DG, CHERESH DA: Integrins and angiogenesis. Curr. Top. Dev. Biol. (2004) 64:207-238.
   PubMed Web of Science ®Google Scholar
• ELICEIRI BP, CHERESH DA: The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. (1999) 103:1227-1230.
   PubMed Web of Science ®Google Scholar
• CHENG JQ, GODWIN AK, BELLACOSA A et al.: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA (1992) 89:9267-9271.
   PubMed Web of Science ®Google Scholar
• SUN M, WANG G, PACIGA JE et al.: AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. (2001) 159:431-437.
   PubMed Web of Science ®Google Scholar
• BELLACOSA A, DE FEO D, GODWIN AK et al.: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer (1995) 64:280-285.
   PubMed Web of Science ®Google Scholar
• SHAYESTEH L, LU Y, KUO WL et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. (1999) 21:99-102.
   PubMed Web of Science ®Google Scholar
• PHILP AJ, CAMPBELL IG, LEET C et al.: The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. (2001) 61:7426-7429.
   PubMed Web of Science ®Google Scholar
• KUROSE K, ZHOU XP, ARAKI T et al.: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. (2001) 158:2097-2106.
   PubMed Web of Science ®Google Scholar
• YUAN ZQ, SUN M, FELDMAN RI et al.: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene (2000) 19:2324-2330.
   PubMed Web of Science ®Google Scholar
• DAN HC, SUN M, KANEKO S et al.: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. (2004) 279:5405-5412.
   PubMed Web of Science ®Google Scholar
• CHENG JQ, JIANG X, FRASER M et al.: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updat. (2002) 5:131-146.
   PubMed Web of Science ®Google Scholar
• MARSHALL CJ: Cell signalling. Raf gets it together. Nature (1996) 383:127-128.
   PubMed Web of Science ®Google Scholar
• ADJEI AA, CROGHAN GA, ERLICHMAN C et al.: A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. (2003) 9:2520-2526.
   PubMed Web of Science ®Google Scholar
• LAHN M, KOHLER G, SUNDELL K et al.: Protein kinase C α expression in breast and ovarian cancer. Oncology (2004) 67:1-10.
   PubMed Web of Science ®Google Scholar
• GRAFF JR, MCNULTY AM, HANNA KR et al.: The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. (2005) 65:7462-7469.
   PubMed Web of Science ®Google Scholar
• ZHANG L, CONEJO-GARCIA JR, KATSAROS D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. (2003) 348:203-213.
   PubMed Web of Science ®Google Scholar
• WILLEMSE PH, DE VRIES EG, MULDER NH et al.: Intraperitoneal human recombinant interferon α-2b in minimal residual ovarian cancer. Eur. J. Cancer (1990) 26:353-358.
   PubMed Web of Science ®Google Scholar
• WINDBICHLER GH, HAUSMANINGER H, STUMMVOLL W et al.: Interferon-γ in the first-line therapy of ovarian cancer: a randomized Phase III trial. Br. J. Cancer (2000) 82:1138-1144.
   PubMed Web of Science ®Google Scholar
• BRUZZONE M, RUBAGOTTI A, GADDUCCI A et al.: Intraperitoneal carboplatin with or without interferon-α in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol. Oncol. (1997) 65:499-505.
   PubMed Web of Science ®Google Scholar
• PUJADE-LAURAINE E, GUASTALLA JP, COLOMBO N et al.: Intraperitoneal recombinant interferon γ in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. (1996) 14:343-350.
   PubMed Web of Science ®Google Scholar
• FRASCI G, TORTORIELLO A, FACCHINI G et al.: Carboplatin and α-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study. Eur. J. Cancer (1994) 30A:946-950.
   PubMed Web of Science ®Google Scholar
• EDWARDS RP, GOODING W, LEMBERSKY BC et al.: Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J. Clin. Oncol. (1997) 15:3399-3407.
   PubMed Web of Science ®Google Scholar
• EHLEN TG, HOSKINS PJ, MILLER D et al.: A pilot Phase II study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer (2005) 15:1023-1034.
   PubMed Web of Science ®Google Scholar
• BEREK JS, TAYLOR PT, GORDON A et al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. (2004) 22:3507-3516.
   PubMed Web of Science ®Google Scholar
• PFISTERER J, DU BOIS A, SEHOULI J et al.: The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol. (2006) 17:1568-1577.
   PubMed Web of Science ®Google Scholar
• SABBATINI P, DUPONT J, AGHAJANIAN C et al.: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res. (2006) 12:5503-5510.
   PubMed Web of Science ®Google Scholar
• REINARTZ S, KOHLER S, SCHLEBUSCH H et al.: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res. (2004) 10:1580-1587.
   PubMed Web of Science ®Google Scholar
• CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10:942-949.
   PubMed Web of Science ®Google Scholar
• KIEBACK DG, PRESS MF, ATKINSON EN et al.: Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL). Anticancer Res. (1993) 13:2489-2496.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, ISEMINGER KA, HATCH KD et al.: Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol. Oncol. (1996) 62:4-6.
   PubMed Web of Science ®Google Scholar
• SLEVIN ML, HARVEY VJ, OSBORNE RJ et al.: A Phase II study of tamoxifen in ovarian cancer. Eur. J. Cancer Clin. Oncol. (1986) 22:309-312.
   PubMedGoogle Scholar
• EMONS G, PAHWA GS, ORTMANN O et al.: LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J. Steroid Biochem. Mol. Biol. (1990) 37:1003-1006.
   PubMed Web of Science ®Google Scholar
• RON IG, WIGLER N, MERIMSKY O et al.: A Phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest. (1995) 13:272-275.
   PubMed Web of Science ®Google Scholar
• DUFFAUD F, VAN DER BURG ME, NAMER M et al.: D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study. Anticancer Drugs (2001) 12:159-162.
   PubMed Web of Science ®Google Scholar
• HOFSTRA LS, MOURITS MJ, DE VRIES EG et al.: Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Anticancer Res. (1999) 19:3627-3630.
   PubMed Web of Science ®Google Scholar
• DEL CARMEN MG, FULLER AF, MATULONIS U et al.: Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol. Oncol. (2003) 91:596-602.
   PubMed Web of Science ®Google Scholar
• VERMA S, ALHAYKI M, LE T et al.: Phase II study of exemestane (E) in refractory ovarian cancer (ROC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5026.
   Google Scholar
• GOURLEY JFS C, MACKEAN M, STEVENSON A et al.: Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), (2006):5025.
   Google Scholar
• FARMER H, MCCABE N, LORD CJ et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434:917-921.
   PubMed Web of Science ®Google Scholar
• GRAZIANI G, SZABO C: Clinical perspectives of PARP inhibitors. Pharmacol. Res. (2005) 52:109-118.
   PubMed Web of Science ®Google Scholar
• OLIVIER RI, VAN BEURDEN M, VAN' T VEER LJ: The role of gene expression profiling in the clinical management of ovarian cancer. Eur. J. Cancer (2006) 42:2930-2938.
   PubMed Web of Science ®Google Scholar
• DE SMET F, POCHET NL, ENGELEN K et al.: Predicting the clinical behavior of ovarian cancer from gene expression profiles. Int. J. Gynecol. Cancer (2006) 16(Suppl. 1):147-151.
   PubMed Web of Science ®Google Scholar
• MATEI D, GRAEBER TG, BALDWIN RL et al.: Gene expression in epithelial ovarian carcinoma. Oncogene (2002) 21:6289-6298.
   PubMed Web of Science ®Google Scholar
• PAIK S, SHAK S, TANG G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. (2004) 351:2817-2826.
   PubMed Web of Science ®Google Scholar
• PEROU CM, SORLIE T, EISEN MB et al.: Molecular portraits of human breast tumours. Nature (2000) 406:747-752.
   PubMed Web of Science ®Google Scholar
• SORLIE T, PEROU CM, TIBSHIRANI R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA (2001) 98:10869-10874.
   PubMed Web of Science ®Google Scholar
• DRESSMAN HK, BERCHUCK A, CHAN G et al.: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. (2007) 25:517-525.
   PubMed Web of Science ®Google Scholar
• NEIL FINKLER AG, CROZIER M, EDWARDS R et al.: Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. (2001) 20:831.
   Google Scholar
• SCHILDER EK RJ, SILL MW, LEWANDOWSKI G, LEE RB, DECESARE SL: Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer: Gynecology Oncology Group 170C. Proc. Am. Soc. Clin. Oncol. (2003) 22:1814.
   Google Scholar
• COLEMAN RL, BROADDUS RR, BODURKA DC et al.: Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol. (2006) 101:126-131.
   PubMed Web of Science ®Google Scholar